Detalhe da pesquisa
1.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621400
2.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028967
3.
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Lancet Oncol
; 21(9): 1213-1223, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888453
4.
Correction to: Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR).
Qual Life Res
; 27(10): 2593, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30014457
5.
Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR).
Qual Life Res
; 27(10): 2581-2591, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29915979